The Prognostic Value of Serum Biomarkers in Osteosarcoma

Istituto Ortopedico Rizzoli600 enrolled

Overview

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Osteosarcoma

Interventions

case series review of clinical dataOTHER

Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Osteosarcoma diagnosed at the Pathological Anatomy of the Rizzoli Orthopaedic Institute in Bologna; * Minimum 2-year follow-up period; * Medical records, complete blood work and instrumental examinations, regular follow-up; * Patients with age ≥ 2 years; Exclusion Criteria: * Patients with osteosarcoma who have received medical treatment (surgery, radiotherapy or chemotherapy) in other hospitals prior to admission to our Institute

Locations (1)

IRCCS Itituto Ortopedico Rizzoli

Bologna, BO, Italy

Outcomes

Primary Outcomes

Evaluation of 5-year survival

Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental prognostic factors

Time frame: 5 years

Secondary Outcomes

Evaluation of the rate of local recurrence

Evaluation of the rate of local recurrence and distant metastasis in relation to histological, laboratory, clinical, and instrumental prognostic factors.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.